Sai Life Sciences has announced its financial results for the second quarter of FY27, reporting a robust 23% year-on-year revenue growth. The company also saw healthy performance in both CRO and CDMO segments, with EBITDA margins standing at 28%. This strong quarter is expected to be followed by a similarly strong second half, driven by the development pipeline and new capacity ramp-up.
Strong Financial Performance in Q2 FY27
Sai Life Sciences has reported a healthy financial performance for the second quarter of Fiscal Year 2027 (Q2 FY27). Revenue from operations saw a significant increase of 23% compared to the same period in the previous year. This growth was broad-based, with both the Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) divisions delivering strong results.
Key Financial Highlights
The company’s EBITDA margins remained strong, standing at 28% for the quarter. Sai Life Sciences anticipates a strong second half of FY27, supported by the ongoing progression of its development and commercial pipeline, as well as the ramp-up of new capacities. The capacity and capability expansion program is proceeding as planned, with a total of ₹621 crore invested in the first half of FY27 (H1 FY27).
H1 FY27 Snapshot
For the first half of FY27 (H1 FY27), the company reported revenue of ₹1,213 crore, a 17% year-on-year increase. Material Margin stood at ₹893 crore (19% YoY growth), EBITDA at ₹335 crore (19% YoY growth), and Profit After Tax (PAT) at ₹172 crore (19% YoY growth). The CDMO revenue mix was 62%, and the CRO revenue mix was 38%. Capex incurred during H1 FY27 was ₹621 crore.
Q2 FY27 Quarterly Snapshot
In Q2 FY27 specifically, revenue was ₹659 crore (23% YoY growth). Material Margin was ₹484 crore (22% YoY growth), EBITDA was ₹187 crore (20% YoY growth), and PAT was ₹98 crore (17% YoY growth). The CDMO revenue mix was 64%, and CRO revenue mix was 36%. Capacity utilization stood at 67%, with Capex incurred in Q2 FY27 at ₹358 crore.
Consolidated Financials
On a consolidated basis, for Half Yearly FY27, revenue was ₹1,213 crore (17% YoY Growth) and material margin was ₹893 crore (19% YoY Growth). EBITDA was ₹335 crore (19% YoY Growth) and PAT was ₹172 crore (19% YoY Growth). For Quarterly FY27, revenue was ₹659 crore (23% YoY Growth), material margin was ₹484 crore (22% YoY Growth), EBITDA was ₹187 crore (20% YoY Growth), and PAT was ₹98 crore (17% YoY Growth).
Business Updates
The company has commenced operations with its first end-to-end integrated collaboration, expected to be fully functional in Q3. It is also working on expanding its integrated outsourcing model and has added one molecule to its late-phase pipeline, with another advanced to commercialization. Capex spend for 6M FY27 was ₹621 Crores, which is on track for the overall projection of ₹1,100 to 1,300 Crores. Additionally, Unit 2 and Unit 4 received Zero Waste to Landfill Platinum certification, and the company has been certified as a Great Place To Work for 2026–27.
Source: BSE
